Aethlon Medical's Hemopurifier Targets Long COVID Symptoms in Innovative Pre-Clinical Study

Aethlon Medical Advances Treatment for Long COVID with Hemopurifier

Aethlon Medical, Inc. is making significant strides in the fight against Long COVID, a debilitating condition affecting millions of Americans, with its recent pre-clinical study focusing on the Hemopurifier®. This innovative device targets extracellular vesicles (EVs), which play a pivotal role in the symptoms associated with Long COVID, including fatigue and cognitive difficulties. The study, conducted in collaboration with the University of California San Francisco Medical Center, examines the increased mannosylation of EVs in the plasma of patients suffering from Long COVID. By employing a proprietary affinity resin containing Galanthus nivalis agglutinin (GNA), the Hemopurifier is designed to bind and eliminate these harmful vesicles from the bloodstream, potentially alleviating the persistent effects of the condition.

The findings from the study reveal that Long COVID patients have elevated levels of both large (100-500 nm) and small (40-200 nm) EVs compared to recovered individuals. Notably, the presence of mannose-positive large EVs is significantly higher in this patient population, suggesting a potential therapeutic target. The study highlights that the GNA affinity resin's effectiveness in removing small EVs correlates with the presence of mannose-positive large EVs, indicating a crucial link that could be exploited for treatment purposes. These insights underscore the Hemopurifier's promising role in addressing the complex challenges posed by Long COVID, which has seen over $1 billion allocated to research without yielding effective treatments thus far.

Aethlon Medical's commitment to tackling the Long COVID crisis reflects the growing need for effective therapeutic options. As the estimated economic burden of this condition reaches $2 billion, the development and potential success of the Hemopurifier could have far-reaching implications for patient care and healthcare costs. Further investigation into the efficacy of the Hemopurifier is essential, as it may represent a beacon of hope for those affected by Long COVID and the medical community at large.